• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA
Click for more information
6.98% 23.0¢

PHARMAUST LIMITED - Announcements

Market Cap $82.69M  ! watchlist Created with Sketch. Add to my watchlist

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PAA American Assoc for Cancer accepts Late-Breaking Abstract06/03/15
PAA Second Cancer Patient Completes Course With Stable DiseasePRICE SENSITIVE05/03/15
PAA Appendix 4D and Half Yearly Report & AccountsPRICE SENSITIVE26/02/15
PAA Further Update on New Anti-Cancer Drug PPL-1 in Human TrialPRICE SENSITIVE24/02/15
PAA Human Trial Prelim Results Shows Reduction in Tumour MarkersPRICE SENSITIVE09/02/15
PAA Clarification to Quarterly Report & Company Update03/02/15
PAA Appendix 4C - Quarterly Report & Company UpdatePRICE SENSITIVE30/01/15
PAA Shareholder Update - Human & Canine TrialsPRICE SENSITIVE20/01/15
PAA Change of Director's Interest Notice08/12/14
PAA Lowest Dosing Cohort with PPL-1 in Dogs Fully RecruitedPRICE SENSITIVE01/12/14
PAA Change of Director's Interest Notice26/11/14
PAA Change of Director's Interest Notice25/11/14
PAA Change of Director's Interest Notice24/11/14
PAA Second Patient In Human Cancer Trial Begins Treatment24/11/14
PAA Research Collaboration & Joint Patent with Japanese CompanyPRICE SENSITIVE18/11/14
PAA Change of Director's Interest Notice13/11/14
PAA Approval received to continue with Human Cancer TrialPRICE SENSITIVE10/11/14
PAA Initial Director's Interest Notice24/10/14
PAA Results of Annual General Meeting24/10/14
PAA AGM Shareholder Presentation24/10/14
PAA First Two Patients in Canine Clinical Trial Begin TreatmentPRICE SENSITIVE22/10/14
PAA Human Cancer Trial Advancing To Second PatientPRICE SENSITIVE21/10/14
PAA Appendix 4C Quarterly & Company UpdatePRICE SENSITIVE14/10/14
PAA Clinical Trial in Dogs is now open for accrualPRICE SENSITIVE02/10/14
PAA Notice of Annual General Meeting/Proxy Form23/09/14
PAA Annual Report23/09/14
PAA Initiation of Clinical Trial in DogsPRICE SENSITIVE09/09/14
PAA Appendix 4E & Full Year Statutory AccountsPRICE SENSITIVE28/08/14
PAA Release from escrow - Appendix 3B & Form 60527/08/14
PAA Human Cancer Trial - First Patient Initiates TreatmentPRICE SENSITIVE07/08/14
PAA Appendix 4C - Quarterly Report & Company UpdatePRICE SENSITIVE25/07/14
PAA Human Cancer Trial InitiationPRICE SENSITIVE23/06/14
PAAChange of Director's Interest Notice x 320/05/14
PAAClinical Study with PPL-1 Initiated following ApprovalPRICE SENSITIVE19/05/14
PAAAppendix 4C - quarterlyPRICE SENSITIVE30/04/14
PAAApproval Received for a Clinical Study in Man with PPL-1PRICE SENSITIVE15/04/14
PAAKey Licence Provided by NewSouth InnovationsPRICE SENSITIVE09/04/14
PAACancer Trial Application with Royal Adelaide HospitalPRICE SENSITIVE25/03/14
PAAAppendix 4D & Half Yearly Report and AccountsPRICE SENSITIVE28/02/14
PAAInterview With Dr Roger Aston27/02/14
PAAApproval of Clinical Trial in DogsPRICE SENSITIVE20/02/14
PAAPharmAust Investor Presentation - February 201418/02/14
PAAImportant Discovery in Cancer TherapyPRICE SENSITIVE17/02/14
PAAChange of Director's Interest Notice15/01/14
PAAAccreditation as Animal Research EstablishmentPRICE SENSITIVE19/12/13
PAATreatment of Canine CancersPRICE SENSITIVE05/12/13
PAAChange of Director's Interest Notice02/12/13
PAAAssignment of intellectual property by NewSouth InnovationsPRICE SENSITIVE19/11/13
PAAAppendix 3B & s708 Notice15/11/13
PAAPharmAust Receives Broker Research Report12/11/13
PAAAppendix 4C - quarterlyPRICE SENSITIVE01/11/13
PAAInitial Director's Interest Notice30/10/13
PAAFinal Director's Interest Notice30/10/13
PAAResults of Annual General Meeting29/10/13
PAAPharmAust AGM 2013 Presentation29/10/13
PAAPharmAust subsidiary Epichem celebrates its 10th anniversary23/10/13
PAAInterview With Dr Roger Aston15/10/13
PAASPP Shortfall Heaily OversubscribedPRICE SENSITIVE01/10/13
PAAAppendix 3B & s708 Notice01/10/13
PAANotice of Annual General Meeting/Proxy Form27/09/13
PAAWholesale Investor Capital Showcase Presentation24/09/13
PAAChange of Director's Interest Notice18/09/13
PAAAppendix 3B16/09/13
PAAClosure of Share Purchase Plan16/09/13
PAAShareholder Update02/09/13
PAAAppendix 4E & Full Year Statutory AccountsPRICE SENSITIVE30/08/13
PAAOptions Prospectus20/08/13
PAAShare Purchase Plan offer documents20/08/13
PAADirector Appointments20/08/13
PAANotice of initial substantial holder x 314/08/13
PAASettlement Of Pitney Pharmaceuticals Acquisition13/08/13
PAAInitial Director's Interest Notice x 212/08/13
PAAs708 Notice and Appendix 3B12/08/13
PAAFinal Director's Interest Notice12/08/13
PAAResignation of Bryant Mclarty as a Director12/08/13
PAAs708 Notice12/08/13
ADX +ADX Buys Back Further 10% Interest in LamboukaPRICE SENSITIVE09/09/11
PAAAnnual Report to Shareholders01/10/10
ADX +Lambouka-1 Well Preliminary Resource EstimatesPRICE SENSITIVE23/09/10
ADX +Lambouka-1 Well Operations Update No. 10PRICE SENSITIVE14/09/10
PAAADX: Lambouka-1 Decision to suspend Well08/09/10
ADX +Commentary on Oil and Gas Project07/09/10
ADX +Lambouka-1 Well ResultsPRICE SENSITIVE07/09/10
PAATrading Halt (amended 'end' date)06/09/10
PAARequest for Trading Halt06/09/10
PAATrading HaltPRICE SENSITIVE06/09/10
PAAPreliminary Final ReportPRICE SENSITIVE01/09/10
ADX +Lambouka-1 Operations Update No. 8PRICE SENSITIVE31/08/10
ADX +Lambouka-1 Well Interim Update 2PRICE SENSITIVE30/08/10
ADX +Lambouka-1 Well Operations UpdatePRICE SENSITIVE27/08/10
ADX +Lambouka-1 Operations Update No. 7PRICE SENSITIVE24/08/10
ADX +Lambouka-1 Well UpdatePRICE SENSITIVE19/08/10
ADX +Drilling Update for Lambouka Well 19-08-10PRICE SENSITIVE19/08/10
ADX +Lambouka-1 Operations Update 6 Corrected18/08/10
ADX +Correction to Lambouka-1 Operations Update No.618/08/10
ADX +Lambouka-1 Well Operations Update No. 6PRICE SENSITIVE17/08/10
ADX +Lambouka-1 Well Site ResultsPRICE SENSITIVE16/08/10
ADX +XState Set to Enter Upper Reservoirs In First Tunisian WellPRICE SENSITIVE12/08/10
ADX +Lambouka-1 Well Operations Update No. 5PRICE SENSITIVE10/08/10
ADX +Lambouka 1 Well Operations Update No. 4PRICE SENSITIVE03/08/10
PAA American Assoc for Cancer accepts Late-Breaking Abstract
06/03/15
PAA Second Cancer Patient Completes Course With Stable Disease
05/03/15PRICE SENSITIVE
PAA Appendix 4D and Half Yearly Report & Accounts
26/02/15PRICE SENSITIVE
PAA Further Update on New Anti-Cancer Drug PPL-1 in Human Trial
24/02/15PRICE SENSITIVE
PAA Human Trial Prelim Results Shows Reduction in Tumour Markers
09/02/15PRICE SENSITIVE
PAA Clarification to Quarterly Report & Company Update
03/02/15
PAA Appendix 4C - Quarterly Report & Company Update
30/01/15PRICE SENSITIVE
PAA Shareholder Update - Human & Canine Trials
20/01/15PRICE SENSITIVE
PAA Change of Director's Interest Notice
08/12/14
PAA Lowest Dosing Cohort with PPL-1 in Dogs Fully Recruited
01/12/14PRICE SENSITIVE
PAA Change of Director's Interest Notice
26/11/14
PAA Change of Director's Interest Notice
25/11/14
PAA Change of Director's Interest Notice
24/11/14
PAA Second Patient In Human Cancer Trial Begins Treatment
24/11/14
PAA Research Collaboration & Joint Patent with Japanese Company
18/11/14PRICE SENSITIVE
PAA Change of Director's Interest Notice
13/11/14
PAA Approval received to continue with Human Cancer Trial
10/11/14PRICE SENSITIVE
PAA Initial Director's Interest Notice
24/10/14
PAA Results of Annual General Meeting
24/10/14
PAA AGM Shareholder Presentation
24/10/14
PAA First Two Patients in Canine Clinical Trial Begin Treatment
22/10/14PRICE SENSITIVE
PAA Human Cancer Trial Advancing To Second Patient
21/10/14PRICE SENSITIVE
PAA Appendix 4C Quarterly & Company Update
14/10/14PRICE SENSITIVE
PAA Clinical Trial in Dogs is now open for accrual
02/10/14PRICE SENSITIVE
PAA Notice of Annual General Meeting/Proxy Form
23/09/14
PAA Annual Report
23/09/14
PAA Initiation of Clinical Trial in Dogs
09/09/14PRICE SENSITIVE
PAA Appendix 4E & Full Year Statutory Accounts
28/08/14PRICE SENSITIVE
PAA Release from escrow - Appendix 3B & Form 605
27/08/14
PAA Human Cancer Trial - First Patient Initiates Treatment
07/08/14PRICE SENSITIVE
PAA Appendix 4C - Quarterly Report & Company Update
25/07/14PRICE SENSITIVE
PAA Human Cancer Trial Initiation
23/06/14PRICE SENSITIVE
PAAChange of Director's Interest Notice x 3
20/05/14
PAAClinical Study with PPL-1 Initiated following Approval
19/05/14PRICE SENSITIVE
PAAAppendix 4C - quarterly
30/04/14PRICE SENSITIVE
PAAApproval Received for a Clinical Study in Man with PPL-1
15/04/14PRICE SENSITIVE
PAAKey Licence Provided by NewSouth Innovations
09/04/14PRICE SENSITIVE
PAACancer Trial Application with Royal Adelaide Hospital
25/03/14PRICE SENSITIVE
PAAAppendix 4D & Half Yearly Report and Accounts
28/02/14PRICE SENSITIVE
PAAInterview With Dr Roger Aston
27/02/14
PAAApproval of Clinical Trial in Dogs
20/02/14PRICE SENSITIVE
PAAPharmAust Investor Presentation - February 2014
18/02/14
PAAImportant Discovery in Cancer Therapy
17/02/14PRICE SENSITIVE
PAAChange of Director's Interest Notice
15/01/14
PAAAccreditation as Animal Research Establishment
19/12/13PRICE SENSITIVE
PAATreatment of Canine Cancers
05/12/13PRICE SENSITIVE
PAAChange of Director's Interest Notice
02/12/13
PAAAssignment of intellectual property by NewSouth Innovations
19/11/13PRICE SENSITIVE
PAAAppendix 3B & s708 Notice
15/11/13
PAAPharmAust Receives Broker Research Report
12/11/13
PAAAppendix 4C - quarterly
01/11/13PRICE SENSITIVE
PAAInitial Director's Interest Notice
30/10/13
PAAFinal Director's Interest Notice
30/10/13
PAAResults of Annual General Meeting
29/10/13
PAAPharmAust AGM 2013 Presentation
29/10/13
PAAPharmAust subsidiary Epichem celebrates its 10th anniversary
23/10/13
PAAInterview With Dr Roger Aston
15/10/13
PAASPP Shortfall Heaily Oversubscribed
01/10/13PRICE SENSITIVE
PAAAppendix 3B & s708 Notice
01/10/13
PAANotice of Annual General Meeting/Proxy Form
27/09/13
PAAWholesale Investor Capital Showcase Presentation
24/09/13
PAAChange of Director's Interest Notice
18/09/13
PAAAppendix 3B
16/09/13
PAAClosure of Share Purchase Plan
16/09/13
PAAShareholder Update
02/09/13
PAAAppendix 4E & Full Year Statutory Accounts
30/08/13PRICE SENSITIVE
PAAOptions Prospectus
20/08/13
PAAShare Purchase Plan offer documents
20/08/13
PAADirector Appointments
20/08/13
PAANotice of initial substantial holder x 3
14/08/13
PAASettlement Of Pitney Pharmaceuticals Acquisition
13/08/13
PAAInitial Director's Interest Notice x 2
12/08/13
PAAs708 Notice and Appendix 3B
12/08/13
PAAFinal Director's Interest Notice
12/08/13
PAAResignation of Bryant Mclarty as a Director
12/08/13
PAAs708 Notice
12/08/13
ADX +ADX Buys Back Further 10% Interest in Lambouka
09/09/11PRICE SENSITIVE
PAAAnnual Report to Shareholders
01/10/10
ADX +Lambouka-1 Well Preliminary Resource Estimates
23/09/10PRICE SENSITIVE
ADX +Lambouka-1 Well Operations Update No. 10
14/09/10PRICE SENSITIVE
PAAADX: Lambouka-1 Decision to suspend Well
08/09/10
ADX +Commentary on Oil and Gas Project
07/09/10
ADX +Lambouka-1 Well Results
07/09/10PRICE SENSITIVE
PAATrading Halt (amended 'end' date)
06/09/10
PAARequest for Trading Halt
06/09/10
PAATrading Halt
06/09/10PRICE SENSITIVE
PAAPreliminary Final Report
01/09/10PRICE SENSITIVE
ADX +Lambouka-1 Operations Update No. 8
31/08/10PRICE SENSITIVE
ADX +Lambouka-1 Well Interim Update 2
30/08/10PRICE SENSITIVE
ADX +Lambouka-1 Well Operations Update
27/08/10PRICE SENSITIVE
ADX +Lambouka-1 Operations Update No. 7
24/08/10PRICE SENSITIVE
ADX +Lambouka-1 Well Update
19/08/10PRICE SENSITIVE
ADX +Drilling Update for Lambouka Well 19-08-10
19/08/10PRICE SENSITIVE
ADX +Lambouka-1 Operations Update 6 Corrected
18/08/10
ADX +Correction to Lambouka-1 Operations Update No.6
18/08/10
ADX +Lambouka-1 Well Operations Update No. 6
17/08/10PRICE SENSITIVE
ADX +Lambouka-1 Well Site Results
16/08/10PRICE SENSITIVE
ADX +XState Set to Enter Upper Reservoirs In First Tunisian Well
12/08/10PRICE SENSITIVE
ADX +Lambouka-1 Well Operations Update No. 5
10/08/10PRICE SENSITIVE
ADX +Lambouka 1 Well Operations Update No. 4
03/08/10PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
23.0¢ 		Change
0.015(6.98%) 		Mkt cap ! $82.69M
Open High Low Value Volume
21.5¢ 23.0¢ 21.5¢ $475.3K 2.128M

Buyers (Bids)

No. Vol. Price($)
4 93524 22.5¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 71004 2
View Market Depth
Last trade - 16.10pm 14/10/2024 (20 minute delay) ?
PAA (ASX) Chart

Top Stories

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Sales growth pushes Lovisa's fortunes (and shares) upwards Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
Scientific conference spotlights PYC's work on blindness disease treatment PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.